VoiceMed, a digital health company developing voice-based solutions for respiratory health, has launched two new clinical studies to validate the use of vocal biomarkers for monitoring patients with Chronic Obstructive Pulmonary Disease (COPD) and predicting exacerbations.
The studies will be conducted in collaboration with San Camillo Forlanini Hospital, ranked as Italy’s top public hospital for pneumology in the 2025 Newsweek classification, and Policlinico Umberto I, one of the largest and oldest hospitals in Europe. Up to 1’000 COPD patients are expected to be enrolled.
Patients will be followed at home for up to 12 months, recording daily voice samples alongside standard monitoring, including oxygen saturation, heart rate, and symptom questionnaires. The goal is to assess the clinical validity of vocal biomarkers for detecting disease progression and predicting exacerbations, and to compare their usability with existing monitoring tools.
“We have completed 5 clinical studies in hospital settings, with European clinical partners. Now, we are doing the big shift to a real-world environment. Launching these studies means moving closer to demonstrating clinical value and patient usability in a domestic environment, where patients will use the tool autonomously without supervision. These patients often show low adherence to therapy and to monitoring protocols. Finding effective ways to push them towards effective disease management is a game-changer for chronic patients, and this is what we are aiming to do.” said Silvia Losardo, clinical affairs manager at VoiceMed.
By combining vocal analysis with artificial intelligence, VoiceMed aims to provide an efficient, convenient and scalable solution for remote respiratory monitoring, enabling earlier intervention and improving continuity of care.
About VoiceMed
VoiceMed is a digital health company developing voice-based solutions for remote monitoring of chronic respiratory issues. By analyzing vocal biomarkers, VoiceMed aims to support earlier insights into patient health, enabling more proactive and data-driven care models.